[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Friedrich RE, Blake FA: Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients. Anticancer Res; 2007 Jul-Aug;27(4A):1841-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
  • Over the past three years, several reports have been published on jaw osteonecrosis possibly being associated with the administration of bisphosphonates.
  • These drugs are used for the treatment of multiple myeloma, bone resorption in the case of metastatic malignant diseases, tumor-associated hypercalcaemia, and in the treatment of osteoporosis.
  • These osteonecroses did not react adequately to local treatment and systemic therapy with antibiotics.
  • One patient suffered from non-Hodgkin's lymphoma, one from breast cancer, one from prostate cancer and one from sarcoidosis.
  • DISCUSSION: Bisphosphonates are considered an established standard in the treatment of multiple myeloma and bone metastases.
  • Over the past few years, a rapidly increasing number of reports have been published describing patients with a history of bisphosphonate therapy in whom therapy-resistant osteonecrosis of jaw bones occurred either after dental extractions or spontaneously.
  • Since then, bisphosphonate therapy has come under scrutiny as a cause of osteonecrosis.
  • However, the multiplicity of drugs prescribed for the treatment of cancer requires caution when determining a cause-and-action effect.
  • Since patients with malignant diseases receive cytostatic therapy and a range of other drugs, including bisphosphonates, enhancement of the side-effects may be presumed.
  • The case report of an osteonecrosis of the jaw following multi-drug therapy for sarcoidosis adds a further and non-cancerous condition to the newly described entity of bisphosphonate-associated jaw necrosis.
  • CONCLUSION: The probable association of the therapeutic use of bisphosphonates and the development of jaw necrosis has to be studied in further investigations.
  • Patients who will undergo bisphosphonate therapy should receive a careful dental check-up prior to drug application.
  • Moreover, established jaw lesions must be diagnosed precisely in order to exclude metastatic disease.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Female. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Middle Aged. Prostatic Neoplasms / drug therapy. Sarcoidosis / drug therapy

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649782.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


2. König M, Mork J, Hall KS, Osnes T, Meling TR: Multimodal treatment of osteogenic sarcoma of the jaw. Skull Base; 2010 May;20(3):207-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment of osteogenic sarcoma of the jaw.
  • Osteosarcomas (OSs) account for 40 to 60% of primary malignant bone tumors.
  • True en bloc resection was performed after upfront adjuvant chemotherapy.
  • Subsequently, a hemimandibulectomy, total parotidectomy, ICA sacrifice, and removal of the pterygoid plates and muscles were performed, and the abovementioned structures were removed as a solitary specimen, including the facial nerve branches overlying the tumor.
  • He has no tumor recurrence 26 months after surgery.
  • OS of the jaw should be treated with radical surgery as the primary modality.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2008 Oct;63(4):651-60; dicussion 660-1 [18824944.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Sep;64(3):302-7 [2443891.001]
  • [Cites] J Neurosurg. 1985 May;62(5):667-72 [3989589.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Oral Oncol. 2001 Oct;37(7):545-7 [11564573.001]
  • [Cites] Laryngoscope. 1999 Jun;109(6):964-9 [10369291.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):191-7 [9180229.001]
  • [Cites] Int J Oral Maxillofac Surg. 1997 Jun;26(3):198-204 [9180230.001]
  • [Cites] Head Neck. 1997 Sep;19(6):513-23 [9278760.001]
  • [Cites] J Otolaryngol. 2004 Jun;33(3):139-44 [15841989.001]
  • [Cites] Oral Oncol. 2008 Mar;44(3):286-94 [17467326.001]
  • [Cites] Head Neck. 2008 Aug;30(8):1020-6 [18383528.001]
  • (PMID = 21318040.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3037111
  • [Keywords] NOTNLM ; Osteosarcoma / craniofacial surgery / en bloc resection / jaw tumor / tumor of the skull base
  •  go-up   go-down


3. Van Poznak C, Estilo C: Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park); 2006 Aug;20(9):1053-62; discussion 1065-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
  • Cases of osteonecrosis of the jaw (ONJ) have been reported with an increasing frequency over the past few years.
  • ONJ is most often identified in patients with cancer who are receiving intravenous bisphosphonate therapy but it has also been diagnosed in patients receiving oral bisphosphonates for nonmalignant conditions.
  • Although it is often associated with a recent dental surgical procedure, spontaneous ONJ can also occur.
  • Through case reporting and clinical experience, there is a suggestion that the incidence of ONJ in patients with cancer receiving intravenous bisphosphonates ranges between 1% and 10%.
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Humans. Jaw / surgery. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Oral Surgical Procedures

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986349.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 71
  •  go-up   go-down


Advertisement
4. Kellie SJ, Koopmans P, Earl J, Nath C, Roebuck D, Uges DR, De Graaf SS: Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer; 2004 Jun 15;100(12):2637-43
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Vincristine (VCR) is widely used to treat patients with malignant disease; among the patients treated with VCR are children with brain tumors.
  • The diagnoses included intrinsic pontine glioma (n = 4), ependymoma (n = 5), astrocytoma (n = 3), medulloblastoma/primitive neuroectodermal tumor (PNET; n = 2), ganglioglioma (n = 1), and choroid plexus carcinoma (n = 1).
  • Treatment included cyclophosphamide 65 mg/kg administered intravenously over 1 hour on Day 1, a bolus of VCR 1.5 mg/m(2) administered intravenously on Day 2, and VCR 0.5 mg/m(2) per 24 hours administered via continuous intravenous infusion on Days 2-5.
  • Fifteen patients received 2 courses of treatment at 21-28-day intervals, and a total of 31 treatment courses were administered.
  • RESULTS: Jaw pain, constipation, mild abdominal pain, and depressed reflexes were common.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Vincristine / administration & dosage. Vincristine / pharmacokinetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Humans. Infant. Infusions, Intravenous. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15197807.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. N'Golet A, N'Gouoni BG, Moukassa D, Nkoua-Mbon JB: Maxillary African histoplasmosis: unusual diagnostic problems of an unusual presentation. Pathol Res Pract; 2005;200(11-12):841-4
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among bone lesions of African histoplasmosis, those affecting the jaw are relatively rare and concern, with other facial involvements, particularly infants and adolescent patients with an usual uncompromised immunologic status.
  • As clinical and radiologic features are not specific, the differential diagnosis to other mandibular diseases is difficult.
  • As it is impossible to confront the histologic diagnosis with mycologic tests in such a situation, the problems of the differential diagnosis to other deep fungus infections and to some yeast-like foreign body-granulomas encountered at the microscopical level underline the importance of culturing organisms from lesions to confirm the histologic diagnosis.
  • It is worth considering this pathology at least for three reasons: it usually mimicks a malignant jaw tumor; it may constitute a migrant pathology; and prognosis is commonly favorable with amphotericin B treatment.
  • [MeSH-minor] Adolescent. Africa. Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Diagnosis, Differential. Humans. Injections, Intravenous. Jaw Neoplasms / diagnosis. Male. Skin Ulcer / drug therapy. Skin Ulcer / microbiology. Skin Ulcer / pathology

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792130.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


6. Palmieri A, Pezzetti F, Brunelli G, Ilaria Z, Carinci F: A comparison between genetic portraits of normal osteoblasts and osteosarcoma cell lines. Indian J Dent Res; 2009 Jan-Mar;20(1):52-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteosarcoma (OS) is the most frequent malignant bone tumor occurring in young patients in the first two decades of life.
  • Metastases are the cause of 90% of cancer deaths for patients with OS.
  • OS of the jaw is rare and aggressive malignancy constitutes approximately 5-13% of all cases of skeletal OS.
  • Chemotherapy plus surgery are the first choice for treatment.
  • AIMS: Because OS cell lines (OCLs) should share a common pathway with primary OS and new drugs are screened in in vitro systems, new insight about the genetic profiling of OCLs is of paramount importance to a better understanding of the molecular mechanism of this rare tumor and detecting a potential target for specific therapy.
  • CONCLUSION: The reported data can be relevant to a better understanding of the biology of OS and as a model for comparing the effect of drugs used in OS treatment.
  • [MeSH-major] Biomarkers, Tumor / genetics. Bone Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Osteoblasts / cytology. Osteosarcoma / genetics
  • [MeSH-minor] Apoptosis / genetics. Cell Differentiation / genetics. Cell Line, Tumor. Cells, Cultured. Gene Expression Profiling. Genes, cdc. Humans. Immunity, Cellular / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336861.001).
  • [ISSN] 1998-3603
  • [Journal-full-title] Indian journal of dental research : official publication of Indian Society for Dental Research
  • [ISO-abbreviation] Indian J Dent Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK: Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates? J Craniomaxillofac Surg; 2005 Dec;33(6):395-403
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
  • INTRODUCTION: In the last decade, bisphosphonates were regularly used to treat osteoporosis and bone pain from diseases such as metastatic breast cancer, multiple myeloma and Paget's disease.
  • Currently, the influence of bisphosphonates in development of avascular osteonecrosis of the jaws has been recognized by various authors.
  • In many cancer patients chemotherapy and medications like steroids have also to be applied.
  • Agreement exists that these drugs can initiate vascular endothelial cell damage and accelerate disturbances in the microcirculation of the jaws possibly resulting in thrombosis of nutrient end arteries.
  • The role of bisphosphonates in cancer patients with previously treated jaws has yet to be elucidated.
  • PATIENTS: Four case reports of 'cancer' patients are described in whom osteonecrosis of the jaws was found.
  • In two patients, the nitrogen-containing bisphosphonate zoledronic acid was prescribed for additional therapy of malignancy for a period of 45 up to 70 months.
  • In another case, supportive treatment of breast cancer was offered using ibandronate.
  • In any case, revisional, as well as extended surgery has to be performed for osteonecrosis because neither conservative debridement nor antibiotic therapy have shown long term success, with or without bisphosphonates.
  • No withdrawal of bisphosphonates was performed in view of the information on the direct correlation of total dosage and duration of drug intake to systemic incorporation and the long time for drug release.
  • CONCLUSION: According to our observations, withdrawal of bisphosphonates is not recommended when necrosis of the jaws has occurred.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253510.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 114084-78-5 / ibandronic acid; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


8. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN: Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res; 2008 Jun;23(6):826-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.
  • INTRODUCTION: Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates.
  • The incidence and risk factors associated with this disorder have not been clearly defined.
  • RESULTS: Sixteen of 1338 patients with breast cancer (1.2%) and 13 of 548 patients with multiple myeloma (2.4%) developed ONJ.
  • The median dose and duration of treatment with pamidronate or zoledronic acid were significantly higher in patients with ONJ (p < 0.0001).
  • Multivariate Cox proportional hazards regression analysis identified treatment with zoledronic acid (hazards ratio [HR], 15.01; 95% CI: 2.41-93.48; p = 0.0037), treatment with pamidronate followed by zoledronic acid (HR, 4.00; 95% CI: 0.86-18.70; p = 0.078), and dental extractions (HR, 53.19; 95% CI: 18.20-155.46; p < 0.0001) as significant risks for ONJ in breast cancer.
  • In multiple myeloma, dental extractions (HR, 9.78; 95% CI: 3.07-31.14; p = 0.0001) and osteoporosis (HR, 6.11; 95% CI: 1.56-23.98; p = 0.0095) were significant risk factors while controlling for bisphosphonate therapy.
  • CONCLUSIONS: ONJ is an uncommon but long-lasting disorder that occurs mainly in breast cancer and multiple myeloma patients treated with intravenous bisphosphonates.
  • ONJ resolved in 23% of patients with conservative therapy.

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2006 Dec 27;296(24):2927-38 [17190893.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2278-81 [17135582.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):852-8 [17258449.001]
  • [Cites] Acta Pol Pharm. 2006 Sep-Oct;63(5):450-2 [17357613.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):148-52 [17336086.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 [12359855.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Jun;32(3):289-95 [12767877.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3150-7 [12915606.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] Aust Dent J. 2003 Dec;48(4):268 [14738134.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1189-99 [15028823.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):745-51 [8053405.001]
  • [Cites] J Clin Invest. 1996 Jun 15;97(12):2692-6 [8675678.001]
  • [Cites] N Engl J Med. 1996 Dec 12;335(24):1785-91 [8965890.001]
  • [Cites] Endocr Rev. 1998 Feb;19(1):80-100 [9494781.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):846-54 [10071275.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301 [15598694.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1207-8 [15849220.001]
  • [Cites] N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 [16000365.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8580-7 [16314620.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):842-8 [16314295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):661-9 [16458773.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):945-52 [16484704.001]
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):48-53 [16524863.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):753-61 [16702591.001]
  • [Cites] Haematologica. 2006 Jul;91(7):968-71 [16757414.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):620-3 [16889620.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3951-2 [17114572.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):56-64 [17325848.001]
  • (PMID = 18558816.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 2P30 CA016672 30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Other-IDs] NLM/ PMC2677083
  •  go-up   go-down


9. Afolabi OC, Odukoya O, Arole G, Banjo AF: Evaluation of nucleolar organizer regions in tumours of the jaw bones. Niger Postgrad Med J; 2001 Mar;8(1):7-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of nucleolar organizer regions in tumours of the jaw bones.
  • Silver stained nucleolar proteins (AgNORs) were counted in a variety of jaw bone tumours.
  • In osteosarcomas, the number of AgNORs was also quantified before and after chemotherapy.
  • Malignant bone tumour cells possessed more than five small AgNORs (5.54 +/- 0.44).
  • Nuclei of benign jaw bone tumour cells had less than three (2. 97 +/-0.61).
  • A significant difference in the number of AgNORs between osteosarcoma before chemotherapy (5.76 +/- 0.50) and after chemotherapy (3.89 +/- 1.65) was observed. (P < 0.05).
  • The results of the present study indicate that the AGNOR count might help in determining malignancy, evaluating the effect of chemotherapy, and deciding the prognosis.
  • [MeSH-major] Biomarkers, Tumor / genetics. Jaw Neoplasms / genetics. Nucleolus Organizer Region / pathology
  • [MeSH-minor] Ameloblastoma / genetics. Ameloblastoma / pathology. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Case-Control Studies. Chondrosarcoma / genetics. Chondrosarcoma / pathology. Diagnosis, Differential. Humans. Osteosarcoma / drug therapy. Osteosarcoma / genetics. Osteosarcoma / pathology. Silver Staining

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11487776.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Mardinger O, Givol N, Talmi YP, Taicher S: Osteosarcoma of the jaw. The Chaim Sheba Medical Center experience. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Apr;91(4):445-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the jaw. The Chaim Sheba Medical Center experience.
  • OBJECTIVE: The purpose of this article is to present 14 cases of osteosarcoma of the jaw treated at our medical center from 1989 to 1998.
  • Differences between osteosarcoma of the jaws and osteosarcoma of the long bones are examined.
  • Each patient had a histopathologically established diagnosis of osteosarcoma of the jaw.
  • Records were reviewed for epidemiologic data, treatment modalities, and survival.
  • Histopathologic types included chondroblastic, osteoblastic, fibroblastic, and malignant fibrous histiocytoma-like.
  • Adjuvant therapy included postoperative radiation (5 patients), postoperative chemotherapy (2 patients), and preoperative chemotherapy and postoperative radiation (1 patient).
  • CONCLUSIONS: The results of the present study support the literature indicating that osteosarcoma of the jaw differs from osteosarcoma of the long bones in its biological behavior even though they have the same histologic appearance.
  • Because of differences in tumor characteristics, the introduction of chemotherapy did not dramatically alter the prognosis of osteosarcoma of the jaw.
  • Early diagnosis and radical surgery are the keys to high survival rates.
  • [MeSH-major] Jaw Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Neoplasms / pathology. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Growth Plate / pathology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11312461.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


11. Adamo V, Caristi N, Saccà MM, Ferraro G, Arcanà C, Maisano R, Santini D, Tonini G: Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opin Pharmacother; 2008 Jun;9(8):1351-61
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients.
  • BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe adverse event of long-term use of bisphosphonates that heavily affects the quality of life of cancer patients.
  • OBJECTIVE: To review epidemiologic data, pathobiology, risk factors, diagnosis and management of BRONJ.
  • Dental extractions, daily masticatory traumas, oral infections, chemotherapy and antiangiogenic drugs can also play an active role.
  • Optimization of therapy based on reduction of bisphosphonate doses or exposure time, newer bisphosphonates and biomolecular agents could favorably impact on BRONJ incidence.
  • [MeSH-major] Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced
  • [MeSH-minor] Bone Density Conservation Agents / adverse effects. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Remodeling / drug effects. Bone and Bones / blood supply. Bone and Bones / drug effects. Diagnosis, Differential. Humans. Risk Factors

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473709.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 118
  •  go-up   go-down


12. Gerressen M, Donner A, Jundt G, Jänicke S, Smeets R, Riediger D, Ghassemi A: [High-grade osteosarcoma of the maxillary sinus. A case report]. Mund Kiefer Gesichtschir; 2006 Sep;10(5):347-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Osteosarcoma of the jaw (JOS) constituting 5% to 13% of all osteosarcoma is a locally aggressive malignant mesenchymal tumor with high tendency to local recurrence and the ability to produce tumor osteoid.
  • CASE REPORT: The presented case deals with a 60-year-old male patient suffering from a newly occurred polypous mucosal tumor of the right-sided maxillary alveolar ridge bioptically diagnosed as a granulation tissue polyp first.
  • After transmaxillary resection of the tumor and consultation of a bone tumor reference center the final diagnosis of a high-grade chondroblastic osteosarcoma could be made.
  • The recommended radical resection of the tumor was declined by the patient because of the expected cosmetic consequences.
  • After surgical reduction of the rapidly growing sarcoma chemotherapy according to the COOS/EURO-B.O.S.S. protocol was initiated at a stage when computed tomography showed diffuse metastatic disease to the lungs.
  • Chemotherapy could delay the progress of the disease only temporarily.
  • CONCLUSION: In JOS radical surgical resection is the therapy of first choice.
  • For substantiation of the diagnosis and central registration of the cases a bone tumor reference center should be contacted.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Diagnosis, Differential. Disease Progression. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Apr;91(4):445-51 [11312461.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2311-6 [6573939.001]
  • [Cites] J Craniomaxillofac Surg. 1991 Feb;19(2):90-3 [2037699.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):439-45 [2297634.001]
  • [Cites] Arch Otolaryngol. 1977 Aug;103(8):485-8 [267450.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1985 Jul;60(1):56-60 [3862014.001]
  • [Cites] Quintessence Int. 2004 Mar;35(3):228-33 [15119682.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Oct;55(10):1177-81 [9331247.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):761-6 [1863442.001]
  • [Cites] Laryngoscope. 1997 Jan;107(1):56-61 [9001266.001]
  • [Cites] Am J Surg. 1980 Oct;140(4):572-6 [6932821.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):374-6 [7719220.001]
  • [Cites] Am J Clin Pathol. 1970 Oct;54(4):625-36 [5273163.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Oct;72(4):444-8 [1923444.001]
  • [Cites] J Maxillofac Surg. 1978 Nov;6(4):273-6 [83344.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1555-63 [1893357.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5975-80 [12185601.001]
  • (PMID = 16947065.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol; 2007 May;62(2):148-52
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.
  • In light of recent reports of osteonecrosis of the jaw (ONJ) in cancer patients whose treatment regimens include an intravenous bisphosphonate, Novartis convened an international advisory board of experts in the fields of oral surgery and pathology, medical oncology, metabolic bone disease, and orthopedics to review existing data and provide updated recommendations on the clinical diagnosis, prevention, and management of ONJ in the oncology setting.
  • Recommendations were developed to help guide healthcare professionals in early diagnosis and patient management.
  • It is recommended that patients be encouraged to receive a dental examination prior to initiating bisphosphonate therapy and, if possible, complete any necessary dental procedures (e.g., tooth extraction) prior to initiating bisphosphonate therapy.
  • Patients should receive regular dental visits during bisphosphonate therapy.
  • Patients should be encouraged to practice good oral hygiene and minimize possible jaw trauma.
  • If possible, patients should avoid dental surgery during treatment with bisphosphonates.
  • If exposed bone is observed or reported in the oral cavity at any time (suspected ONJ), refer the patient to a dental professional immediately.
  • [MeSH-major] Jaw Diseases / diagnosis. Jaw Diseases / prevention & control. Jaw Diseases / therapy. Osteonecrosis / diagnosis. Osteonecrosis / prevention & control. Osteonecrosis / therapy
  • [MeSH-minor] Diphosphonates / adverse effects. Guidelines as Topic. Humans. Osteoporosis / drug therapy

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336086.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 50
  •  go-up   go-down


14. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol; 2005 Dec 1;23(34):8580-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
  • PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid.
  • The first bisphosphonate treatment among patients with ONJ was administered in 1997.
  • RESULTS: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289).
  • The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ.
  • The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months.
  • The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor.
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Female. Follow-Up Studies. Greece / epidemiology. Humans. Imidazoles / adverse effects. Imidazoles / therapeutic use. Incidence. Male. Middle Aged. Multiple Myeloma / drug therapy. Multiple Myeloma / pathology. Prospective Studies. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Risk Factors. Time Factors. Treatment Failure

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Maxillofac Surg. 2006 Jun;64(6):995-6 [16713825.001]
  • (PMID = 16314620.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  •  go-up   go-down


15. Werder P, Altermatt HJ, Zbären P, Mueller-Garamvölgyi E, Bornstein MM: Palatal swelling as the first and only manifestation of extranodal follicular non-Hodgkin lymphoma: a case presentation. Quintessence Int; 2010 Feb;41(2):93-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-Hodgkin lymphomas (NHLs) in the head and neck region are malignant lymphoid neoplasms that usually originate from B-lymphocytic cell lines.
  • Primary extranodal manifestations of this hematolymphoid tumor in the oral cavity are rare and involve the maxillary jaw including the palatal soft tissues, the mandible, and gingival tissues in patients between 60 and 70 years of age without sex predilection.
  • This case report of an extra-nodal NHL in the palate of a 75-year-old patient emphasizes the importance of accurate clinical, radiographic, and histologic diagnostic procedures to avoid delayed diagnosis or inappropriate treatment strategies.
  • Chemotherapy, radiotherapy, or a combination of the two with a regular clinical and hemic follow-up is recommended.
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Palate, Soft / pathology. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20165740.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Anand R, Gupta S: Hemangiopericytoma of the maxilla in a pediatric patient: a case report. J Dent Child (Chic); 2010 Sep-Dec;77(3):180-2
Genetic Alliance. consumer health - Hemangiopericytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The hemangiopericytoma is a malignant vascular tumor arising from mesenchymal cells with pericytic differentiation.
  • The tumor is extremely rare in the head and neck region (16%).
  • Surgical resection remains the mainstay treatment.
  • Adjuvant chemotherapy and radiotherapy is appropriate for cases of incomplete resections and life-threatening tumors particularly in children.
  • A 4-year-old child patient with hemangiopericytoma of the maxilla presented with firm, recurrent, but painless jaw mass.
  • The lesion biopsy showed wellcircumscribed multiple lobules of tumor mass consisting of tightly packed, spindleshaped cells.
  • Chemotherapy and radiotherapy of the lesion was conducted.
  • [MeSH-major] Hemangiopericytoma / diagnosis. Maxillary Neoplasms / diagnosis
  • [MeSH-minor] Biopsy. Child, Preschool. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22164890.001).
  • [ISSN] 1935-5068
  • [Journal-full-title] Journal of dentistry for children (Chicago, Ill.)
  • [ISO-abbreviation] J Dent Child (Chic)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Morris M, Cruickshank S: Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. Eur J Oncol Nurs; 2010 Jul;14(3):205-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
  • PURPOSE: This paper reports a review of the literature with a specific focus on osteonecrosis of the jaw.
  • Bisphosphonate drugs are commonly used in the treatment of bone disease secondary to myeloma and solid tumours, such as breast and prostate cancer.
  • In the past few years, an uncommon but distressing condition known as osteonecrosis of the jaw (ONJ) has been detected in patients who are having bisphosphonate treatment, particularly the intravenous (IV) preparations.
  • Osteonecrosis of the jaw results from bone exposure in the oral cavity with subsequent death of bone tissue (necrosis).
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Oncology Nursing / organization & administration. Osteonecrosis / chemically induced
  • [MeSH-minor] Advanced Practice Nursing / organization & administration. Bone Neoplasms / drug therapy. Bone Neoplasms / nursing. Bone Neoplasms / secondary. Drug Monitoring. Humans. Incidence. Nurse's Role. Nursing Assessment. Patient Education as Topic. Practice Guidelines as Topic. Primary Prevention. Risk Factors

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20129822.001).
  • [ISSN] 1532-2122
  • [Journal-full-title] European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • [ISO-abbreviation] Eur J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 49
  •  go-up   go-down


18. Atanasov DT, Indjov SI, Lalabonova HK, Neichev DS: Sarcomas of the mandible. Literature review and case reports. Folia Med (Plovdiv); 2004;46(2):31-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study reports three cases (osteogenic sarcoma, fibrosarcoma, chondrosarcoma) with specific clinical and radiographic characteristics, demonstrating the differences between the various types of sarcomas.
  • Special attention is paid to the first clinical signs and symptoms, and to the differential diagnosis with inflammatory conditions (post-extraction alveolitis, chronic odontogenic osteomyelitis), benign tumors (osteoblastoclastoma, ameloblastoma, odontogenic cysts, fibrous dysplasia) and centrally developing jaw carcinomas.
  • Particular emphasis is given to CT imaging and morphological examinations in making an accurate diagnosis and providing adequate treatment.
  • Early diagnosis and precise surgical treatment (total resection or hemiexarticulation, or neck dissection if submandibular or cervical metastases are present) are essential to achieve satisfactory management of these malignant neoplasms.
  • The radiotherapy and chemotherapy administered according to the histologic features of the tumor are also of significance.
  • [MeSH-major] Chondrosarcoma / diagnosis. Fibrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15506548.001).
  • [ISSN] 0204-8043
  • [Journal-full-title] Folia medica
  • [ISO-abbreviation] Folia Med (Plovdiv)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Bulgaria
  • [Number-of-references] 21
  •  go-up   go-down


19. Ottaviani G, Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res; 2009;152:3-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among childhood cancers, osteosarcoma occurs eighth in general incidence and in the following order: leukemia (30%), brain and other nervous system cancers (22.3%), neuroblastoma (7.3%), Wilms tumor (5.6%), Non-Hodgkin lymphoma (4.5%), rhabdomyosarcoma (3.1%), retinoblastoma (2.8%), osteosarcoma (2.4%), and Ewing sarcoma (1.4%).
  • The most common sites are the femur (42%, with 75% of tumors in the distal femur), the tibia (19%, with 80% of tumors in the proximal tibia), and the humerus (10%, with 90% of tumors in the proximal humerus).
  • Other likely locations are the skull or jaw (8%) and the pelvis (8%).
  • Cancer deaths due to bone and joint malignant neoplasms represent 8.9% of all childhood and adolescent cancer deaths.
  • Tumor staging, presence of metastases, local recurrence, chemotherapy regimen, anatomic location, size of the tumor, and percentage of tumor cells destroyed after neoadjuvant chemotherapy have effects on the outcome.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213383.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


20. Schirmer I, Peters H, Reichart PA, Dürkop H: [Bisphosphonates and osteonecrosis of the jaw]. Mund Kiefer Gesichtschir; 2005 Jul;9(4):239-45
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bisphosphonates and osteonecrosis of the jaw].
  • BACKGROUND: Since 2003, reports have been published on necrosis of the jaw bones possibly being associated with the administration of bisphosphonates.
  • Bisphosphonates are highly active inhibitors of osteoclasts which have been used prophylactically or symptomatically in the treatment of plasmocytoma, bone metastasis of malignant disease, tumor-associated hypercalcaemia and in the treatment of osteoporosis.
  • These osteonecroses did not react adequately to local treatment and systemic therapy with antibiotics.
  • Four patients suffered from plasmocytoma and two patients had a history of metastasising breast cancer.
  • DISCUSSION: Bisphosphonates are considered an important standard in the treatment of plasmocytoma and bone metastasis due to malignancies.
  • Since 2003, several reports have been published describing patients in whom therapy resistant osteonecrosis of jaw bones occurred either after dental extractions or spontaneously.
  • Until then, unknown side effects of bisphosphonate therapy had been suspected.
  • Since patients with malignant diseases receive cytostatic therapy and a range of other drugs, including bisphosphonates, enhancement of the side effects may be presumed.
  • CONCLUSIONS: The probable association of the therapeutic use of bisphosphonates and the occurence of jaw bone necrosis has to be studied in further investigations.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced. Plasmacytoma / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Jaw / pathology. Male. Middle Aged. Radiography, Panoramic

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Sep;98(3):259-60 [15356460.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Oct;61(10):1238-9 [14586868.001]
  • [Cites] Am J Med. 2004 Sep 15;117(6):440-1 [15380503.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Mar;62(3):391-2 [15015179.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):763-4 [15181903.001]
  • [Cites] Aust Dent J. 2003 Dec;48(4):268 [14738134.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • (PMID = 15918066.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


21. Bonomi M, Nortilli R, Molino A, Sava T, Santo A, Caldara A, Cetto GL: Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Med Oncol; 2010 Jun;27(2):224-9
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis.
  • BACKGROUND: Bisphosphonates (BPs) are the mainstay of bone-directed therapy for bone metastases from multiple myelomas and a wide range of solid tumours, but some patients experience renal toxicity or osteonecrosis of the jaw (ONJ).
  • PATIENTS AND METHODS: We reviewed data relating to 398 patients treated with intravenous BP for bone metastases, checking their serum creatinine levels throughout the treatment period in order to assess renal function, and seeking any signs and symptoms of ONJ recorded in their medical records.
  • We also analysed other risk factors for renal toxicity and ONJ in patients who developed them.
  • RESULTS: The median treatment period was 14 months (range 1-119); 108 patients received BP for more than 1 year, and 112 for more than 2 years.
  • Sixteen patients (4%) developed renal toxicity after a median of 24 months of BP treatment, eight of them had been treated for more than 2 years.
  • However, prevention and early detection are still the "first-line therapy" for decreasing their occurrence further.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Bone Neoplasms / drug therapy. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Oncol. 2010 Jun;27(2):568 [19472089.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2613-21 [15197804.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):556-60 [17082512.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3434-7 [11454892.001]
  • [Cites] Oncologist. 2005 Nov-Dec;10(10):842-8 [16314295.001]
  • [Cites] Ann Oncol. 2006 Oct;17 (10 ):1512-6 [16936182.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2552-9 [8823335.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2038-44 [9626201.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):508-14 [16750501.001]
  • [Cites] N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 [16000365.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68 [12359855.001]
  • [Cites] Am J Otolaryngol. 2007 May-Jun;28(3):158-63 [17499130.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):593-602 [9469347.001]
  • [Cites] J Oncol Pract. 2006 Jan;2(1):7-14 [20871729.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8580-7 [16314620.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):369-76 [17307580.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):682-9 [15883944.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):1016-24 [17596574.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1197-204 [16873439.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3314-21 [15738536.001]
  • [Cites] J Craniofac Surg. 2006 Nov;17(6):1080-3 [17119409.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75 [16243172.001]
  • [Cites] N Engl J Med. 1996 Dec 12;335(24):1785-91 [8965890.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:14-27 [15459426.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4042-57 [12963702.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2007 Aug 01;12(4):E336-40 [17664922.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):897-907 [16547070.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • (PMID = 19330470.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates
  •  go-up   go-down


22. Park JY, Kim HS, Zo JI, Lee S, Choi SW: Initial presentation of lung sarcomatoid carcinoma as a metastatic lesion in the mandibular gingiva. J Periodontol; 2006 Apr;77(4):734-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sarcomatoid carcinoma of the lung is a very rare type of tumor characterized by distant metastasis.
  • Occasionally, an oral metastatic lesion may be the preliminary clinical feature observed before the diagnosis of the primary tumor.
  • A 55-year-old male patient presented with a rapidly growing pedunculated exophytic mass on the gingiva at the left side of the lower jaw.
  • RESULTS: The histologic and immunohistochemical diagnosis was metastatic carcinoma.
  • To locate the primary tumor, we analyzed the lung lesion by chest computerized tomography (CT) scans and biopsy.
  • Palliative chemotherapy for lung cancer was administered.
  • The gingival lesion disappeared after chemotherapy.
  • CONCLUSION: Although this case is unusual, periodontists should recognize that gingival masses similar to benign or inflammatory lesions may represent an initial sign of underlying malignant tumors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584358.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Bodner L, Sion-Vardy N, Geffen DB, Nash M: Metastatic tumors to the jaws: a report of eight new cases. Med Oral Patol Oral Cir Bucal; 2006 Mar;11(2):E132-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumors to the jaws: a report of eight new cases.
  • PATIENTS AND METHODS: The records of 8 patients with metastatic jaw lesions were reviewed.
  • Demographic data, presenting symptoms, primary tumor site, radiographic findings, bone scintigraphy , histopathology and clinical management were analyzed.
  • The primary malignant sites were: the lung , the breast , the rectum, the thyroid, the uterus and the parotid gland .
  • The clinical jaw presentations were: exophytic soft tissue mass, paresthesia of the lower lip and a periapical lesion The provided treatment protocols were: chemotherapy , radiotherapy and chemotherapy, surgery and chemotherapy and supportive care only.
  • In one case the jaw lesion was the first indication of an unknown malignancy at a distant primary site.
  • CONCLUSIONS: Metastatic jaw lesions are uncommon.
  • Paresthesia of the lower lip and the chin is a sinister sign for patients with a metastatic jaw lesion.
  • In view of these cases it can be said that meticulous work-up of of jaw lesions suspected of being metastatic, may be life saving or extend the patient s survival period.
  • [MeSH-major] Carcinoma / secondary. Jaw Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16505790.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Anand R, Gupta S: Hemangiopericytoma of maxilla in a pediatric patient: a case report. J Dent Child (Chic); 2010 Sep-Dec;77(3):180-2
Genetic Alliance. consumer health - Hemangiopericytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Hemangiopericytoma is a malignant vascular tumor arising from mesenchymal cells with pericytic differentiation.
  • The tumor is extremely rare in the head and neck region (16%)1.
  • Surgical resection remains the mainstay treatment.
  • Adjuvant chemotherapy and radiotherapy is appropriate for cases of incomplete resections and life-threatening tumors particularly in children.
  • A 4-year-old child patient with hemangiopericytoma of the maxilla presented with firm, recurrent, but painless jaw mass.
  • The lesion biopsy showed well-circumscribed multiple lobules of tumor mass consisting of tightly packed, spindle-shaped cells.
  • Chemotherapy and radiotherapy of the lesion was conducted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2001 Jun;36(6):908-12 [11381424.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2692-8 [11745205.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):62-5 [12165454.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1746-51 [12365023.001]
  • [Cites] Cancer. 1978 Apr;41(4):1256-60 [346193.001]
  • [Cites] Am J Surg. 1984 Sep;148(3):372-4 [6476228.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 May-Jun;19(3):247-50 [9201149.001]
  • [Cites] Ann Surg Oncol. 1998 Jun;5(4):350-5 [9641457.001]
  • (PMID = 21785578.001).
  • [ISSN] 1935-5068
  • [Journal-full-title] Journal of dentistry for children (Chicago, Ill.)
  • [ISO-abbreviation] J Dent Child (Chic)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA076023-02; United States / NCI NIH HHS / CA / R25 CA076023; United States / NCI NIH HHS / CA / R25 CA076023-02
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS136956; NLM/ PMC3140132
  • [Keywords] NOTNLM ; Chemotherapy / Hemangiopericytoma / Prognosis / Radiotherapy / Vascular tumor
  •  go-up   go-down


25. Aboul-hosn Centenero S, Marí-Roig A, Piulachs-Clapera P, Juárez-Escalona I, Monner-Diéguez A, Díaz-Carandell A, Lluch JM, Pericot-Ayats J: Primary intraosseous carcinoma and odontogenic cyst. Three new cases and review of the literature. Med Oral Patol Oral Cir Bucal; 2006 Jan;11(1):E61-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The Odontogenic Primary Intraosseous Carcinoma (PIOC) are a rare group of malignant tumours with strict clinic and anatomy pathological diagnosis criteria.
  • Two of them in the posterior jaw region where is more frequent, and the third in the upper jaw.
  • We explain the procedure we used in each case and the aesthetic-functional reconstruction used witches are two fibula osteomyocutaneous free flaps and a bone graft of iliac crest and further placing of implants.
  • The classification, the clinical and radiological diagnosis, the treatment and its survival are discussed.
  • RESULTS: In all three cases we were able to see in the anatomy pathological study an epithelial, exclusively without surrounding oral mucosa affectation or tissues near the lesion as well as the lack of tumorous pathology in other parts of the body.
  • CONCLUSIONS: The anatomy pathological study of all of the lesions of cystic characteristics at jaw level is very important because of the risk of coexisting with carcinomatous cells.
  • The treatment of these tumours consists in practising aggressive surgery and, in some cases, radio and/or chemotherapy post intervention.
  • [MeSH-major] Jaw Neoplasms / pathology. Odontogenic Cysts / pathology. Odontogenic Tumor, Squamous / pathology. Precancerous Conditions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16388297.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 15
  •  go-up   go-down


26. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS: Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med; 2008 Jun;121(6):475-483.e3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with osteonecrosis of the jaw among bisphosphonate users.
  • BACKGROUND: Bisphosphonates are medications that impact bone reformation by inhibiting osteoclast function.
  • Osteonecrosis of the jaw has been reported among patients receiving these medications.
  • It is unclear if the risk factors associated with osteonecrosis of the jaw among cancer patients taking bisphosphonates also are possible risk factors among patients receiving these medications for other indications.
  • METHODS: A systematic review search strategy was used to identify cases of osteonecrosis of the jaw among patients taking bisphosphonates for an indication other than cancer to identify potential contributing factors.
  • Data were analyzed according to previous models to develop a more expanded model that may explain possible mechanisms for the development of osteonecrosis of the jaw among patients without cancer.
  • RESULTS: Ninety-nine cases of osteonecrosis of the jaw were identified among patients who were prescribed a bisphosphonate for an indication other than cancer.
  • Of the 63 patients reporting dental care information, 88.9% had a dental procedure before the onset of osteonecrosis of the jaw.
  • Of all cases providing medical information, 71% were taking at least one medication that affects bone turnover in addition to the bisphosphonate, and 81.3% reported additional underlying health conditions.
  • CONCLUSIONS: The case details suggest a multiplicity of factors associated with this condition and provide the foundation for a model outlining the potential mechanism for the development of osteonecrosis of the jaw among patients taking bisphosphonates for an indication other than cancer.

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • [Cites] J Bone Miner Res. 2007 Oct;22(10):1479-91 [17663640.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] Aust Dent J. 2003 Dec;48(4):268 [14738134.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] Hypertension. 1995 Mar;25(3):305-13 [7875754.001]
  • [Cites] J Bone Joint Surg Am. 1995 Apr;77(4):616-24 [7713981.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Sep;84(3):229-30 [9377182.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jan;85(1):64-73 [9474617.001]
  • [Cites] Med J Aust. 2005 Apr 18;182(8):413-5 [15850439.001]
  • [Cites] Med J Aust. 2005 Apr 18;182(8):417-8 [15850440.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):83-93 [15929121.001]
  • [Cites] Med J Aust. 2005 Aug 1;183(3):163-4 [16053423.001]
  • [Cites] Harefuah. 2005 Aug;144(8):536-9, 600, 599 [16146148.001]
  • [Cites] Minerva Stomatol. 2005 Jul-Aug;54(7-8):441-8 [16211002.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75 [16243172.001]
  • [Cites] J Craniomaxillofac Surg. 2005 Dec;33(6):395-403 [16253510.001]
  • [Cites] Presse Med. 2005 Sep 10;34(15):1073-7 [16334883.001]
  • [Cites] J Mich Dent Assoc. 2005 Nov;87(11):44-9 [16372548.001]
  • [Cites] Mund Kiefer Gesichtschir. 2005 Jul;9(4):233-8 [16395774.001]
  • [Cites] Aust Dent J. 2005 Dec;50(4 Suppl 2):S4-13 [16416712.001]
  • [Cites] Singapore Dent J. 2005 Dec;27(1):36-40 [16438267.001]
  • [Cites] Laryngoscope. 2006 Jan;116(1):115-20 [16481822.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):753-61 [16702591.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):508-14 [16750501.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):588-93 [16687238.001]
  • [Cites] J Am Dent Assoc. 2006 Aug;137(8):1115-9; quiz 1169-70 [16873327.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1100-3 [16901034.001]
  • [Cites] Aust Fam Physician. 2006 Oct;35(10):801-3 [17019456.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2278-81 [17135582.001]
  • [Cites] Acta Biomed. 2006 Aug;77(2):109-17 [17172192.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):415-23 [17307586.001]
  • [Cites] Ann Pharmacother. 2007 Feb;41(2):276-84 [17299010.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Mar;136(3):396-400 [17321866.001]
  • [Cites] Support Care Cancer. 2007 Feb;15(2):197-202 [16941133.001]
  • [Cites] J Periodontol. 2007 Mar;78(3):584-94 [17335384.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1172-5 [17179196.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):747-53 [17341572.001]
  • [Cites] Bone. 2007 Apr;40(4):828-34 [17236837.001]
  • [Cites] Therapie. 2007 Jan-Feb;62(1):49-54 [17374348.001]
  • [Cites] N Engl J Med. 2007 May 3;356(18):1809-22 [17476007.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):780-6 [17223592.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1139-45 [17569974.001]
  • [Cites] Endocr Pract. 2007 May-Jun;13(3):232-8 [17599853.001]
  • [Cites] Radiol Med. 2007 Jun;112(4):603-11 [17563854.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1841-5 [17649782.001]
  • [Cites] Br Dent J. 2007 Jul 28;203(2):93-7 [17660780.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2007 Aug;12(4):E267-71 [17664910.001]
  • [Cites] J Am Dent Assoc. 2007 Sep;138(9):1218-20 [17785387.001]
  • [CommentIn] Am J Med. 2008 Dec;121(12):e21; author reply e23 [19028185.001]
  • (PMID = 18501224.001).
  • [ISSN] 1555-7162
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / P30 CA023074-30; United States / NCI NIH HHS / CA / R25 CA078447; United States / NCI NIH HHS / CA / CA078447-09; None / None / / P30 CA023074-30; United States / NCI NIH HHS / CA / R25T-CA078447; United States / NCI NIH HHS / CA / R25 CA078447-09; United States / NCI NIH HHS / CA / P30-CA023074
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 57
  • [Other-IDs] NLM/ NIHMS52888; NLM/ PMC2601671
  •  go-up   go-down


27. Benateau H, Rigau V, Martin JP, Labbé D, Compère JF: [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature]. Rev Stomatol Chir Maxillofac; 2000 Apr;101(2):80-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature].
  • [Transliterated title] Difficultés diagnostiques du chondrosarcome des maxillaires. A propos d'un cas et revue de la littérature.
  • Chondrosarcoma is an uncommon malignant mesenchymal tumor characterized by the production of cartilaginous tissue and the absence of production of bone tissue.
  • The clinical and radiographic findings are similar to those seen in other tumors of the jaw, often delaying diagnosis and treatment and subsequently jeopardizing prognosis.
  • In the literature, the mean delay from first clinical signs to diagnosis is about 8 months.
  • As in all tumoral diseases, pathology confirms the diagnosis.
  • We report a case of chondrosarcoma of the maxillary bone and review the literature, focusing on the difficulty in establishing the diagnosis, even at the pathology examination.
  • We propose wide surgical excision, which, in agreement with other reports in the literature, is the only therapeutic possibility.
  • Radiotherapy and chemotherapy may be useful in certain cases.
  • [MeSH-major] Chondrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone and Bones / pathology. Cartilage / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Mandible / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859759.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 40
  •  go-up   go-down


28. Wobser R, Wilpert J, Kayser G, Walz G, Stubanus M: [Disseminated histoplasmosis with involvement of mediastinum and skin in an immunocompetent patient]. Dtsch Med Wochenschr; 2009 Mar;134(12):589-93
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Disseminierte Histoplasmose mit Befall des Mediastinums und der Haut bei immunkompetenter Patientin.
  • She reported a noticeable swelling at the right mandible and an ulcerative tumor at the side of the nose.
  • Computed tomography revealed extensive, confluent lymphoma.
  • There were groups of cervical lymph nodes, especially in the area of the right jaw.
  • DIAGNOSIS: Bronchial biopsy revealed necrotizing, granulomatous inflammation with dense infiltration of lymphatic cells.
  • Histological work-up of the ulcerating tumor at the side of the nose also showed Histoplasma capsulatum.
  • TREATMENT AND COURSE: 8 weeks after starting specific treatment with oral itraconazole the inflammatory parameters had fallen to normal and computed tomography showed regression of the mediastinal bulge.
  • CONCLUSION: Large mediastinal and cervical lymphatic masses with space-occupying bronchial lesions suggest should, in the differential diagnosis, consider not only malignant tumor but also infections.
  • [MeSH-major] Antifungal Agents / therapeutic use. Histoplasmosis / diagnosis. Histoplasmosis / drug therapy. Itraconazole / therapeutic use. Mediastinum / pathology. Skin / pathology
  • [MeSH-minor] Adult. Bronchi / parasitology. Bronchi / pathology. Female. Histoplasma / isolation & purification. Humans. Inflammation / drug therapy. Inflammation / microbiology. Necrosis

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277935.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole
  •  go-up   go-down


29. Kyrgidis A, Andreadis C: Bisphosphonate osteonecrosis of the jaws in cancer patients. Breast; 2009 Oct;18(5):335
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphosphonate osteonecrosis of the jaws in cancer patients.
  • [MeSH-major] Bone Density Conservation Agents / adverse effects. Breast Neoplasms / pathology. Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Breast. 2009 Aug;18(4):213-7 [19651512.001]
  • (PMID = 19783147.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  •  go-up   go-down


30. Aksoy S, Dizdar O, Altundag K: Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates. Med Oncol; 2010 Jun;27(2):568
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates.
  • [MeSH-major] Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Kidney Diseases / chemically induced. Neoplasms / drug therapy. Osteonecrosis / chemically induced






Advertisement